Federico Rossari

8PUBLICATIONS
44CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 21, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.

Federica Lo Prinzi, Federico Rossari, Antonio De Rosa

|Jul 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.

Federica Lo Prinzi, Francesca Salani, Silvia Camera

|Jul 02, 2025
A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice.

Federico Rossari, Giorgia Alvisi, Melania Cusimano

|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.

Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi

|Nov 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.

Federico Rossari, Toshifumi Tada, Goki Suda

|Oct 09, 2023
The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia.

Daniela Magliulo, Matilde Simoni, Carolina Caserta

Pageof 2

Frequent Collaborators

3 joint publications

Stefano Beretta

3 joint publications

Margherita Rimini

2 joint publications

Filippo Birocchi

2 joint publications

Paola Maria Vittoria Rancoita